Resistance To First-Line Antituberculosis Drugs And Prevalence Of *pncA* Mutations In Clinical Isolates Of *Mycobacterium tuberculosis* From Zunyi, Guizhou Province Of China

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Zhimin Cao¹
Yuanbo Lan¹
Ling Chen¹
Min Xiang¹
Zhiyuan Peng¹
Jianying Zhang¹
Hong Zhang^{1,2}

¹Tuberculosis Division, Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, People's Republic of China; ²Department of R & D, Z-BioMed, Inc, Rockville, MD, 20855, USA

Background: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between *pncA* gene mutations and resistance to four first-line anti-TB drugs as well as treatment history in clinical isolates of *Mycobacterium tuberculosis*.

Patients and methods: *M. tuberculosis* clinical isolates were collected from 318 in-patients with smear-positive TB between October 2008 and September 2016 at a major hospital in Zunyi, Guizhou Province of China, and used for drug susceptibility testing against four first-line anti-TB drugs. Genomic DNA extracted from clinical isolates was used for PCR amplification and DNA sequencing of the *pncA* gene.

Results: Among 318 clinical isolates, 129 (40.6%), 170 (53.5%), 66 (20.8%) and 109 (34.3%) were resistant to rifampicin, isoniazid, ethambutol and streptomycin respectively. In addition, 124 clinical isolates were MDR-TB and 71.8% of them were previously treated cases. Sequencing results showed that 46.8% of MDR-TB and 2.2% of drug susceptible isolates harbored a *pncA* mutation, and 52 types of *pncA* mutations were detected from 64 isolates. The prevalence of *pncA* mutations in isolates resistant to first-line anti-TB drugs and previously treated TB cases was significantly higher than that in drug-susceptible isolates and new cases of TB.

Conclusion: High prevalence of *pncA* mutations in clinical isolates of *M. tuberculosis* from Zunyi, Guizhou Province of China, is correlated with resistance to four first-line anti-TB drugs, MDR-TB and previously treated TB cases.

Keywords: *Mycobacterium tuberculosis*, pyrazinamide, drug resistance, *pncA* mutation

Introduction

Tuberculosis (TB), a chronic infectious disease, caused about 1.6 million deaths globally in 2017, and China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB).¹ The recommended treatment for drug-susceptible TB is a six-month first-line regimen including two months of isoniazid, rifampicin, pyrazinamide and ethambutol followed by four months of isoniazid and rifampicin.¹ Pyrazinamide (PZA or Z) is also one of the antituberculosis drugs used for the shorter MDR-TB treatment regimen with sterilizing and bactericidal activity. Pyrazinamide, a synthetic nicotinamide analog, has to be converted from a pro-drug to its active form

Correspondence: Ling Chen; Hong Zhang
Tuberculosis Division, Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Zunyi, Guizhou 563003, People's Republic of China
Tel +86 851 2860 9237
Fax +86 851 2860 8239
Email lingjuncd@163.com; hzhang@zbiomed.com

pyrazinoic acid (POA) in the cytoplasm by the nicotinamide/pyrazinamidase (PZase). Both PZA and POA have been shown to have different enzyme targets interfering with diverse biochemical pathways involved in the mycobacterial energy metabolism, lipid synthesis and membrane transport.²

Previous studies have shown that PZA resistance in *Mycobacterium tuberculosis* is mainly caused by various mutations in the PZase coding gene, *pncA*, or its promoter region leading to a decrease/loss of PZase activity or reduced expression of *pncA* gene.³ Drug susceptibility testing (DST) against PZA is not routinely performed in most resource-limited regions due to its complexity, inconsistency and high cost. Therefore, an alternative *pncA* gene-sequencing method was developed to detect mutations in the *pncA* gene and to rapidly screen for PZA susceptibility with 90.9% of sensitivity and 100% of specificity.⁴ Currently, DNA sequencing of the *pncA* gene is the proposed reference method for DST against PZA because there is no WHO recommended rapid method.⁵ In a systematic review of mutations reported in 61 studies, 641 unique mutations in 171 out of 187 codons of the *pncA* gene (561 bp) and its promoter region from 2,760 PZA-resistant isolates and 96 mutations from 3,329 PZA-susceptible isolates were recognized.³ In another study, more than 300 mutations were identified through in vitro saturating mutagenesis of the *pncA* gene which mapped throughout the entire *pncA* coding region and conferred resistance to PZA.⁶

It was reported from a multicountry surveillance project involving the detection of *pncA* mutations that PZA resistance was significantly associated with rifampicin-resistant TB (RR-TB) cases.⁷ Other studies showed that 74% of PZA-resistant TB isolates from Pakistan, more than half of MDR/RR-TB isolates from Sub-Saharan Africa countries and Georgia, and 37.5% of PZA-resistant TB isolates from Yunnan, China, had a mutation in the *pncA* gene⁸⁻¹² However, it was unclear whether similar correlations could be observed in clinical isolates of *M. tuberculosis* from Zunyi, China. The aim of this study was to determine the correlation between *pncA* gene mutations and resistance to four first-line anti-TB drugs, MDR-TB as well as treatment history in clinical isolates of *M. tuberculosis* from a major hospital in Zunyi, Guizhou Province of China.

Patients And Methods

Patients And Clinical Isolates Of *M. tuberculosis*

This study was conducted at the Affiliated Hospital of Zunyi Medical University, a tertiary general hospital in

Zunyi, Guizhou Province of China. A total of 318 in-patients with smear-positive TB were registered at the Tuberculosis Division of Respiratory and Critical Care Medicine of the hospital. Clinical isolates of *M. tuberculosis* were collected from the sputum and bronchoscope brush specimens of 318 TB patients as a part of routine hospital laboratory procedures in a period from October 2008 to September 2016. These clinical isolates were not specifically collected for this study; however, patient identifiers were removed from clinical isolates prior to the initiation of this study. Collected clinical specimens were cultured on Löwenstein-Jensen solid slants by following the procedures recommended by WHO¹³ and grown colonies were identified to the species level using 2-thiophene carboxylic acid and para-nitrobenzoic acid selective media.

Drug Susceptibility Testing

Drug susceptibility testing (DST) of *M. tuberculosis* clinical isolates was conducted at the Laboratory of Respiratory Medicine in the hospital, which was certified by the Chinese Center for Disease Control and Prevention (CCDC). The proportion method on Löwenstein-Jensen solid slants was used for DST against four first-line anti-TB drugs purchased from Sigma-Aldrich (St. Louis, MO, USA). The critical drug concentrations were: 40 µg/mL of rifampicin (RIF), 0.2 µg/mL of isoniazid (INH), 4 µg/mL of streptomycin (SM), and 2 µg/mL of ethambutol (EMB). The standard *M. tuberculosis* strain H37Rv was obtained from the China CDC and used as a control for all the tests. The critical proportion of four first-line anti-TB drugs was one percent and multidrug resistance was defined as resistance to both RIF and INH.

DNA Extraction And PCR Amplification

Genomic DNAs were extracted from 318 clinical isolates of *M. tuberculosis* and the standard H37Rv strain using the cetyltrimethylammonium bromide (CTAB) method. Two oligonucleotide primers, *pncA*-F (5'-GCTGGTCATGTTTCGC GATCG-3') and *pncA*-R (5'-GCTTGCGGCGAGCGCT CCA-3'), were designed by using the Web Primer website (<http://seq.yeastgenome.org/cgi-bin/web-primer>), and used for PCR amplification of the *pncA* gene with purified genomic DNA as a template. The PCR reaction mixture (25 µL) contained 12.5 µL of 2×Taq Master Mix (Beijing TIANGEN Biotech Co., Ltd., China), 0.5 µL of DNA template, and 0.5 µL of each primer pair at a concentration of 20 mM. The thermal cycling conditions were 5 min at 94°C for denaturation followed by 30 cycles of 94°C for 1 min for

denaturation, 60°C for 1 min for annealing, and 72°C for 1 min for amplification; and a final extension of 10 min at 70°C. The amplified PCR products (719bp, genome sequences from 2289345 to 2288626) were verified by agarose gel electrophoresis and sent to Shanghai Invitrogen for sequencing using primers *pncA*-F and *pncA*-R. The sequencing results were analyzed and mutations in the *pncA* gene were identified by aligning them with the wild-type *pncA* gene (GeneID: 887497) of the reference strain H37Rv using the BLAST (bl2seq) program at the NCBI website (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Data Analysis

The chi-square (χ^2) test was used to evaluate the correlation between *pncA* gene mutations in clinical isolates of *M. tuberculosis* and resistance to each of the first-line anti-TB drugs as well as treatment history of TB patients. Differences with a *P* value less than 0.05 were determined to be statistically significant.

Results

Demographic Information About TB Patients

M. tuberculosis clinical isolates were collected consecutively from patients with active pulmonary TB at the hospital between October 2008 and September 2016. Among 318 TB patients, 196 (61.6%) were male and 122 (38.4%) were female; 187 (58.8%) were new cases and 131 (41.2%) were previously treated cases. Patients were divided into three age groups: <35 years (104, 32.7%), 35–55 years (104, 32.7%) and >55 years (110, 34.6%). The average age of patients was 49.3 years, the youngest patient was 13 years old and the oldest patient was 95 years old (Table 1).

Drug Susceptibility Testing Against First-Line Anti-TB Drugs

M. tuberculosis clinical isolates were analyzed for their drug susceptibility profiles against four first-line anti-TB drugs (RIF, INH, EMB, and SM). Among 318 collected clinical isolates, 129 (40.6%), 170 (53.5%), 66 (20.8%) and 109 (34.3%) were resistant to RIF, INH, EMB and SM respectively; 124 (39%) were identified as MDR-TB; 58 (18.2%) were mono-resistant/poly-drug resistant TB (MR/PDR-TB); and 136 clinical isolates (42.8%) were determined to be pan-susceptible to four first-line anti-TB drugs (Pan-S-TB) (Table 1). In addition, 35 out of 124 MDR-TB cases (28.2%), 43 out of 58 MR/PDR-TB cases (74.1%)

and 109 out of 136 Pan-S-TB cases (80.1%) were new cases. Whereas, 89 out of 124 MDR-TB cases (71.8%), 15 out of 58 MR/PDR-TB cases (25.9%) and 27 out of 136 Pan-S-TB cases (19.9%) were previously treated cases (Table 1).

Detection Of *pncA* Mutations In *M. tuberculosis* Clinical Isolates

A total of 136 Pan-S-TB, 124 MDR-TB and 58 MR/PDR-TB isolates were used for DNA extraction and sequencing of the *pncA* gene (Table 1). Two primers, *pncA*-F and *pncA*-R, were designed to amplify a genomic DNA fragment covering the entire *pncA* gene plus extra 104 bp at the 5' end and extra 54 bp at the 3' end. Mutations in the *pncA* gene should not cause possible PCR negatives because both primers were located outside of the *pncA* coding region. The same primer set was also used for sequencing of the amplified PCR products (719bp). Analysis of sequencing results showed that 64 out of 318 clinical isolates (20.1%), including 58 MDR, three PDR and three Pan-S TB isolates had a mutation in the *pncA* gene (Table 2). Among 64 clinical isolates, 52 different types of *pncA* mutations were detected which included point mutations, insertions and deletions. The codon 131 was mutated most frequently (6 out of 64 isolates, five insertions and one point mutation Lys131Phe) followed by codon 76 with 4 isolates and codon 67 with three isolates (Table 2 and Figure 1).

Prevalence Of *pncA* Mutations And Resistance To First-Line Anti-TB Drugs And Treatment History

Among 124 MDR-TB isolates, 58 (46.8%) harbored a mutation in the *pncA* gene, whereas, only three out of 136 Pan-S-TB isolates (2.2%) had a mutation in the *pncA* gene and the difference was statistically significant ($p<0.01$) (Table 3). The prevalence of *pncA* mutations in isolates resistant to four first-line anti-TB drugs was higher than that in drug-susceptible isolates and the differences were also statistically significant ($p<0.01$): 46.5% verse 2.1% for RIF, 34.1% verse 4.1% for INH, 42.4% verse 14% for EMB, and 40.4% verse 9.1% for SM (Table 3). When treatment history of TB patients was considered, the prevalence of *pncA* mutations in previously treated TB cases (36.2%) was much higher than that in the new cases of TB (9%) and the difference was statistically significant ($p<0.01$) (Table 3).

Table 1 Demographic Characteristics And Treatment History Of 318 TB Patients

Characteristics And Treatment History	MDR-TB (n=124)	MR/PDR-TB (n=58)	Pan-S-TB (n=136)	Total (n=318)
	No. (%)	No. (%)	No. (%)	No. (%)
Gender				
Male	75 (60.5%)	39 (67.2%)	82 (60.3%)	196 (61.6%)
Female	49 (39.5%)	19 (32.8%)	54 (39.7%)	122 (38.4%)
Age (years)				
<35	37 (29.8%)	22 (37.9%)	45 (33.1%)	104 (32.7%)
35–55	58 (46.8%)	14 (24.2%)	32 (23.5%)	104 (32.7%)
>55	29 (42.8%)	22 (37.9%)	59 (43.4%)	110 (34.6%)
Average	42.8	45.8	56.7	49.3
Youngest	16	13	16	13
Oldest	83	83	95	95
Treatment history				
New case	35 (28.2%)	43 (74.1%)	109 (80.1%)	187 (58.8%)
Previously treated	89 (71.8%)	15 (25.9%)	27 (19.9%)	131 (41.2%)

Abbreviations: MDR-TB, multidrug-resistant tuberculosis; MR/PDR-TB, monodrug-resistant/poly-drug resistant tuberculosis; Pan-S-TB, pan-susceptible tuberculosis.

Table 2 *pncA* Gene Mutations Detected In 64 Clinical Isolates Of *M. tuberculosis*

Nucleotide Position	Codon Change	Amino Acid Change	Nucleotide Position	Codon Change	Amino Acid Change
11 ^a	TTG4TCG	Leu4Ser	289	GGT97AGT	Gly97Ser
29	CAG10CCG	Gln10Pro	289 ^a	GGT97CGT	Gly97Arg
35	GAC12GCC	Asp12Ala	304	GCG102ACG	Ala102Thr
50	Insertion of G	FSC 17 (ins)	309	TAC103TAG	Tyr103Stop
62	GTA21GCA	Val21Ala	314	Insertion of G	FSC 105 (ins)
63–73	Deletion of AA CCGGTGGCG	FSC 21–25 (del)	338	Insertion of G	FSC 113 (ins)
85	CGC29TGC	Arg29Cys	357	TGG119TGT	Trp119Cys
124	CAT42AAT	His42Asn	362 ^a	CGG121CCG	Arg121Pro
136	Deletion of G	FSC 46 (del)	391 ^b	Insertion of G	FSC 131 (ins)
137	GCA46GTA	Ala46Val	391 ^a	Insertion of GG	FSC 131 (ins)
139 ^a	ACC47GCC	Thr47Ala	391	GTC131TTC	Val131Phe
160	CCG54GCG	Pro54Ala	398	ATT133ACT	Ile133Thr
161	CCG54CAG	Pro54Gln	403	ACC135GCC	Thr135Ala
172	TTC58GTC	Phe58Val	407	GAT136GGT	Asp136Gly
184	CCG62TCG	Pro62Ser	416 ^a	GTG139GCG	Val139Ala
185	CCG62CGC	Pro62Arg	416	GTG139GGG	Val139Gly
193	TCC65CCC	Ser65Pro	422	CAG141CGG	Gln141Arg
200 ^a	TCG67TAG	Ser67Stop	423	CAG141CAC	Gln141His
200	TCG67TTG	Ser67Leu	425	ACG142ATG	Thr142Met
212	CAT71CGT	His71Arg	464	GTG155GAG	Val155Glu
226 ^c	ACT76CCT	Thr76Pro	478	ACA160GCA	Thr160Ala
231	Insertion of G	FSC 77 (ins)	484	GGT162CGT	Gly162Arg
233	GGC78GAC	Gly78Asp	512	GCG171GAG	Ala171Glu
285	Deletion of TAC	FSC 95 (del)	524	ATG175AGG	Met175Arg
285	TAC95TAA	Tyr95Stop	539	GTC180GCC	Val180Ala
286	AAG96CAG	Lys96Gln	554	AGC185ATC	Ser185Ile

Notes: ^aTwo isolates with the same mutation; ^bThree isolates with the same mutation; ^cFour isolates with the same mutation.

Abbreviations: del, deletion; FSC, frame-shift codon; ins, insertion.

Figure 1 Distribution, mutant type and frequency of 64 *pncA* mutations detected in this study. Numbers are amino acid positions in the *pncA* coding region and numbers in brackets represent the number of isolates with the same mutation. Red symbol, MDR-TB; blue symbol, PDR-TB; and green symbol, Pan-S-TB.

Discussion

Pyrazinamide is one of the major anti-TB drugs used for both the first- and second-line regimens, which plays an important role in reducing the treatment duration for drug-susceptible and drug-resistant TB.¹ Drug susceptibility testing against PZA is not routinely performed, and mutations in the *pncA* gene or the *pncA* promoter region have been proved to be the main molecular mechanism causing PZA resistance in clinical isolates of *M. tuberculosis*.³ Therefore, detection of mutations in the *pncA* gene by DNA sequencing is the proposed reference method for rapid screening of PZA susceptibility.^{5,6} Results from a large multicenter study assessing *pncA* sequence variations in 1,950 clinical isolates showed that 888 (45.5%) isolates harbored 280 mutations in the *pncA* gene.¹⁴

During the current study, *M. tuberculosis* clinical isolates were collected from 318 TB patients and the proportion of male to female patients was 61.6% to 38.4%, which was consistent with our previous study for male (62.8%) and female (37.2%) patients.¹⁵ However, the proportion of previously treated cases in this study (41.2%) was higher

than that in our previous study (31%),¹⁵ probably because only in-patients were enrolled in this study. For the same reason, rates of MDR-TB in new (18.7%, 35/187) and previously treated TB cases (69.7%, 89/131) were higher than those in our previous studies¹⁵ and combined data from 53 Member States in the WHO European Region (15.7% of new and 45.3% of previously treated cases of TB were MDR-TB).¹⁶ Most patients from this study (65.4%) were 55 years of age or younger and the average age of patients was 49.3 years (Table 1).

Our PCR and sequencing results showed that the prevalence of *pncA* mutations in clinical isolates resistant to each of the four first-line anti-TB drugs (RIF, INH, EMB and SM), MDR-TB and previously treated TB cases were significantly higher than those in drug-susceptible isolates and new cases of TB (Table 3). The prevalence of *pncA* mutations in MDR-TB isolates (46.8%) collected from Zunyi, Guizhou Province, is lower than that in MDR-TB isolates collected from the neighboring Chongqing Province (57.9%, 77/133),¹⁷ but higher than those in MDR-TB isolates collected from Yunnan Province

Table 3 The Prevalence Of *pncA* Mutations In Drug-Resistant And Drug-Susceptible Isolates Of *M. tuberculosis*, And In Isolates From New And Previously Treated TB Cases

First-Line Drugs And Treatment History	No. Of Isolates Tested	Isolates With <i>pncA</i> Mutation	
		No.	%
Rifampicin			
Resistant	129	60	46.5
Susceptible	189	4	2.1
P value			$p<0.01$ $\chi^2=94.0$
Isoniazid			
Resistant	170	58	34.1
Susceptible	148	6	4.1
P value			$p<0.01$ $\chi^2=54.0$
Ethambutol			
Resistant	66	28	42.4
Susceptible	250	35	14.0
P value			$p<0.01$ $\chi^2=26.4$
Streptomycin			
Resistant	109	44	40.4
Susceptible	208	19	9.1
P value			$p<0.01$ $\chi^2=43.8$
Multidrug-resistant TB	124	58	46.8
Pan-susceptible TB	136	3	2.2
P value			$p<0.01$ $\chi^2=71.7$
New case	188	17	9.0
Previously treated case	130	47	36.2
P value			$p<0.01$ $\chi^2=35.14$

(21.4%, 6/28)¹² and Zhejiang Province (35.4%, 97/274)¹⁸ of China, supporting the suggestion that *pncA* mutations may differ from one geographic region to another based on studies from different regions.¹⁷

To compare the prevalence of *pncA* mutations in MDR/RR, new, previously treated and total cases of TB in different settings around the world, we listed in Table 4 the published data from 32 countries in six WHO regions (Africa, Americas, Eastern Mediterranean, Europe, South-East Asia and Western Pacific). It was obvious that the prevalence of *pncA* mutations in *M. tuberculosis* isolates from different countries and different regions were quite different, consistent with the observation that levels of PZA resistance varied substantially among different settings.⁷ For example, the prevalence of *pncA* mutations in MDR/RR (85%) and total cases of TB (57.9%) from George¹¹ was much higher than that in MDR/RR cases from Turkey (25%)²⁸ and in total

cases of TB from Azerbaijan (12.6%),⁷ even though these three countries were located in the same European region (Table 4). The prevalence of *pncA* mutations among MDR-TB cases from 32 different countries in six WHO regions varied widely ranging from 21.4% in Yunnan Province of China¹² and 39.5% in Pakistan⁷ to 81.3% in Belarus⁷ and 87.8% in Republic of Korea.³⁸ In addition, the prevalence of *pncA* mutations among previously treated TB cases from six WHO regions also varied extensively ranging from 4.7% in South Africa,⁷ 8.9% in Pakistan⁷ and 13.8% in Bangladesh⁷ to 36.2% in Zunyi, China, 66.7% in Rwanda¹⁰ and 70.8% in George.¹¹

Sequencing results also showed that 52 different types of *pncA* mutations were detected from 64 clinical isolates of *M. tuberculosis*, mostly from MDR-TB isolates, but three from PDR-TB and three from Pan-S-TB isolates (Figure 1). The distribution, type, and frequency of 64 *pncA* mutations detected in this study were revealed in Figure 1. Five mutations were new and deposited in GenBank with accession numbers KR534845 (Ser67Stop), KR534846 (Tyr95del), KR534847 (Ser67Leu), KR534848 (Gly105FSC), and KR534849 (Gly113FSC). Based on a multicenter study, Miotto et al divided 280 genetic variants in *pncA* into four classes (i, ii, iii and iv), and class (i) mutations were very high confidence resistance ones that were found only in PZA-resistant strains.¹⁴ Among 52 mutation types (Table 2), 19 belonged in class (i), 2 belonged in class (ii) and 3 belonged in class (iii). Through comparison with the data published by the CRYPTIC consortium on whole-genome analyses of 10,209 isolates,⁴⁰ we found that 25 mutations detected in MDR/PDR-TB isolates and two of three mutations detected in Pan-S isolates (R29C and H42D) fell in the “R” category, and one MDR (S65P) and one Pan-S isolates (Q141H) fell in the “S” category.

It was previously found in a systematic review of mutations reported in 61 studies that 79% of 2,760 PZA-resistant and 9% of 3,329 PZA-susceptible isolates had a mutation in the *pncA* gene,³ suggesting that *M. tuberculosis* clinical isolates with a mutation in the *pncA* gene be more likely resistant to PZA than those without a *pncA* mutation. The comparison results also indicated the existence of geographical diversity of prevalence of *pncA* mutations among *M. tuberculosis* clinical isolates depending on where they were collected. Therefore, we should consider geographical diversity as an important factor when we select screening of *pncA* mutations as a simple method for quick diagnosis of PZA resistance in *M. tuberculosis* isolates, and decide whether PZA should be included in the optimized treatment

Table 4 The Prevalence Of *pncA* Mutations In *M. tuberculosis* Isolates From Six Different WHO Regions And 32 Countries Of The World

Prevalence Of <i>pncA</i> Gene Mutations, % (Number Of TB Isolates Tested)				
WHO Regions	MDR/RR Cases	New Cases	PT Cases	Total Cases
Africa				
Burundi ⁹	65.7% (35)	N/A	N/A	N/A
Sub-Sahara Africa (12 countries) ¹⁰	54.3% (573)	63.9% (72)	49.0% (453)	51.0% (525)
Cameroon ¹⁰	49.6% (133)	55.6% (9)	50% (116)	50.4% (125)
CAR ¹⁰	28.6% (35)	N/A	23.3% (30)	N/A
DRC ¹⁰	73.7% (95)	75% (16)	68.7% (67)	69.9% (83)
Niger ¹⁰	39.6% (48)	N/A	39.1% (46)	N/A
Rwanda ¹⁰	67.3% (101)	69.0% (42)	66.7% (36)	67.9% (78)
Senegal ¹⁰	33.3% (39)	N/A	31.4% (35)	N/A
South Africa ⁷	39.1% (39)	2.8% (648)	4.7% (145)	3.1% (877)
Americas				
Brazil ¹⁹	N/A	N/A	N/A	20.6% (97)
Canada ²⁰	88.5% (26)	N/A	N/A	37.6% (141)
Mexico ²¹	N/A	N/A	N/A	26.7% (127)
Peru ²²	N/A	N/A	N/A	30.9% (68)
Eastern Mediterranean				
Iran ²³	N/A	N/A	N/A	27.3% (33)
Pakistan ⁷	39.5% (103)	2.1% (1,299)	8.9% (201)	3.0% (1,500)
Europe				
Azerbaijan ⁷	59.9% (129)	10.2% (530)	17.9% (218)	12.6% (748)
Belarus ⁷	81.3% (98)	30.0% (144)	69.9% (57)	42.1% (201)
Georgia ¹¹	85.0% (40)	48.5% (33)	70.8% (24)	57.9% (57)
Germany ²⁴	59.8% (82)	N/A	N/A	N/A
Kazakhstan ²⁵	75% (48)	N/A	N/A	49.4% (77)
Russia ²⁶	N/A	N/A	N/A	56.8% (44)
Sweden ²⁷	N/A	N/A	N/A	45.1% (71)
Turkey ²⁸	25% (12)	N/A	N/A	N/A
Ukraine ²⁹	73.6% (91)	N/A	N/A	N/A
South-East Asia				
Bangladesh ⁷	36.7% (63)	2.6% (751)	13.8% (203)	5.1% (955)
India ³⁰	N/A	N/A	N/A	78.0% (50)
Indonesia ³¹	N/A	N/A	N/A	5.6% (322)
Myanmar ³²	60.0% (66)	N/A	N/A	N/A
Thailand ³³	47% (100)	N/A	N/A	32.7% (150)
Western Pacific				
China				
Beijing ³⁴	50% (142)	N/A	N/A	N/A
Chongqing ¹⁷	57.9% (133)	N/A	N/A	57.9% (133)
Jiangsu ³⁵	N/A	N/A	N/A	15.0% (254)
Shanghai ³⁶	N/A	N/A	N/A	41.0% (432)
Sichuan ³⁵	N/A	N/A	N/A	15.2% (408)
Southern China ³⁵	31.0% (129)	N/A	N/A	15.5% (878)
Yunnan ¹²	21.4% (28)	N/A	N/A	11.1% (54)
Zhejiang	35.4% (274) ¹⁸	N/A	N/A	16.7% (216) ³⁵
Zunyi	46.8% (124)	9.0% (188)	36.2% (130)	20.1% (318)
Japan ³⁷	66.7% (36)	N/A	N/A	N/A

(Continued)

Table 4 (Continued).

Prevalence Of <i>pncA</i> Gene Mutations, % (Number Of TB Isolates Tested)				
WHO Regions	MDR/RR Cases	New Cases	PT Cases	Total Cases
Korea ³⁸	87.7% (122)	N/A	N/A	N/A
Viet Nam ³⁹	72.4% (123)	N/A	N/A	38.1% (260)

Abbreviations: CAR, Central African Republic; DRC, Democratic Republic of Congo; MDR/RR-TB, multidrug-resistant/rifampicin-resistant tuberculosis; N/A, not available; PT, previously treated; WHO, World Health Organization.

regimens for TB patients, particularly those from countries with high prevalence of *pncA* mutations in MDR/RR and previously treated TB cases.

Limitations of this study included that we only collected smear-positive specimens to make sure the sputum specimens to be positive of bacteria at the time of collection and to grow enough bacteria for DST and DNA extraction. If we had also collected smear-negative specimens for this study, the overall prevalence of *pncA* mutations would have been lower but should not affect the conclusion of this study. Another limitation was that culture-based phenotypic testing for PZA was not performed on clinical isolates of *M. tuberculosis* due to its technical difficulties.

Conclusion

Results from this study show that high prevalence of *pncA* mutations in clinical isolates of *M. tuberculosis* from Zunyi, Guizhou Province of China, are correlated with resistance to each of the four first-line anti-TB drugs, MDR-TB and previously treated TB cases.

Acknowledgments

We would like to thank the clinical/laboratory staff and graduate students from the Tuberculosis Division of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, for their assistance in collecting clinical data and specimens from patients, and culture of *M. tuberculosis* clinical isolates for drug susceptibility testing during this study. This work was supported by the National Natural Science Foundation of China (NSFC Nos. 81160003, 81360002 and 81760003). The sponsor played no role in the collection, analysis, and interpretation of data, in writing the manuscript, and in the decision to submit the article for publication.

Author Contributions

ZC, YL, MX and ZP carried out the experiments. All authors contributed to data analysis, drafting and revising

the manuscript, agreed to be accountable for all aspects of the work, and approved the final version of the manuscript.

Disclosure

HZ is employed by and has shares in Z-BioMed, Inc., which is involved in infectious disease research. The authors report no other conflicts of interest in this work.

References

1. World Health Organization. Global tuberculosis report. 2018. Available from: http://www.who.int/tb/publications/global_report/en;2018. Accessed July 8, 2019.
2. Stehr M, Elamin AA, Singh M. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria. *Expert Rev Anti Infect Ther*. 2015;13:593–603. doi:10.1586/14787210.2015.1021784
3. Ramirez-Busby SM, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in *Mycobacterium tuberculosis* clinical isolates. *Antimicrob Agents Chemother*. 2015;59:5267–5277. doi:10.1128/AAC.00204-15
4. Streicher EM, Maharaj K, York T, et al. Rapid sequencing of the *Mycobacterium tuberculosis pncA* gene for detection of pyrazinamide susceptibility. *J Clin Microbiol*. 2014;52:4056–4057. doi:10.1128/JCM.02438-14
5. World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. 2018. Available from: <http://apps.who.int/medicinedocs/documents/s23565en/s23565en.pdf>. Accessed July 8, 2019.
6. Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. *Nat Commun*. 2017;8:588. doi:10.1038/s41467-017-00721-2
7. Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of *Mycobacterium tuberculosis* isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. *Lancet Infect Dis*. 2016;16:1185–1192. doi:10.1016/S1473-3099(16)30190-6
8. Khan MT, Malik SI, Ali S, et al. Pyrazinamide resistance and mutations in *pncA* among isolates of *Mycobacterium tuberculosis* from Khyber Pakhtunkhwa, Pakistan. *BMC Infect Dis*. 2019;19:116. doi:10.1186/s12879-019-3764-2
9. Daneau G, Gumusboga M, De Rijk P, et al. The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide. *Int J Mycobacteriol*. 2016; (Suppl 1):S46–S47. doi:10.1016/j.ijmyco.2016.10.015
10. Ngabonziza JCS, Diallo AB, Tagliani E, et al. Half of rifampicin-resistant *Mycobacterium tuberculosis* complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. *PLoS One*. 2017;12:e0187211. doi:10.1371/journal.pone.0187211

11. Sengstake S, Bergval IL, Schuitema AR, et al. Pyrazinamide resistance-conferring mutations in *pncA* and the transmission of multidrug resistant TB in Georgia. *BMC Infect Dis*. 2017;17:491. doi:10.1186/s12879-017-2594-3
12. Li D, Song Y, Zhang CL, Li X, Xia X, Zhang AM. Screening mutations in drug-resistant *Mycobacterium tuberculosis* strains in Yunnan, China. *J Infect Public Health*. 2017;10:630–636. doi:10.1016/j.jiph.2017.04.008
13. World Health Organization. *Laboratory Services in Tuberculosis Control. Part III: Culture*. Geneva: World Health Organization; 1998. Available from: [http://apps.who.int/iris/bitstream/handle/10665/65942/WHO_TB_98.258_\(part3\).pdf;jsessionid=64EF54513AD4144A520B24B4E3DFCBA5?sequence=3](http://apps.who.int/iris/bitstream/handle/10665/65942/WHO_TB_98.258_(part3).pdf;jsessionid=64EF54513AD4144A520B24B4E3DFCBA5?sequence=3). Accessed July 8, 2019.
14. Miotto P, Cabibbe AM, Feuerriegel S, et al. *Mycobacterium tuberculosis* pyrazinamide resistance determinants: a multicenter study. *MBio*. 2014;5:e01819–14. doi:10.1128/mBio.01819-14
15. Lan Y, Li Y, Chen L, Zhang J, Zhang H. Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China. *Infect Drug Resist*. 2019;12:211–219. doi:10.2147/IDR.S188538
16. Zignol M, Dara M, Dean AS, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. *Drug Resist Updat*. 2013;16:108–115. doi:10.1016/j.drug.2014.02.003
17. Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant *Mycobacterium tuberculosis* isolates from Southern China. *BMC Infect Dis*. 2017;17:711. doi:10.1186/s12879-017-2761-6
18. Xia Q, Zhao LL, Li F, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant *Mycobacterium tuberculosis* isolates in Zhejiang, China. *Antimicrob Agents Chemother*. 2015;59:1690–1695. doi:10.1128/AAC.04541-14
19. Bhujra S, Fonseca Lde S, Marsico AG, et al. *Mycobacterium tuberculosis* isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the *pncA* gene. *Infect Genet Evol*. 2013;19:1–6. doi:10.1016/j.meegid.2013.06.008
20. Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. Gene sequencing for routine verification of pyrazinamide resistance in *Mycobacterium tuberculosis*: a role for *pncA* but not *rpsA*. *J Clin Microbiol*. 2012;50:3726–3728. doi:10.1128/JCM.00620-12
21. Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, Fuentes-Dominguez J, Zenteno-Cuevas R. Characterization of *pncA* gene mutations in pyrazinamide-resistant *Mycobacterium tuberculosis* isolates from Mexico. *Infect Genet Evol*. 2013;19:330–334. doi:10.1016/j.meegid.2012.12.013
22. Sheen P, Requena D, Gushiken E, et al. A multiple genome analysis of *Mycobacterium tuberculosis* reveals specific novel genes and mutations associated with pyrazinamide resistance. *BMC Genomics*. 2017;18:769. doi:10.1186/s12864-017-4146-z
23. Kahbazi M, Sarmadian H, Ahmadi A, et al. Novel mutations in *pncA* gene of pyrazinamide resistant clinical isolates of *Mycobacterium tuberculosis*. *Sci Pharm*. 2018;86:pii:15. doi:10.3390/scipharm86020015
24. Andres S, Gröschel MI, Hillemann D, Merker M, Niemann S, Kranzer K. A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in rifampin-resistant *Mycobacterium tuberculosis* isolates in a low-incidence setting. *Antimicrob Agents Chemother*. 2019;63:e01798–18. doi:10.1128/AAC.01798-18
25. Akhmetova A, Kozhamkulov U, Bismilda V, et al. Mutations in the *pncA* and *rpsA* genes among 77 *Mycobacterium tuberculosis* isolates in Kazakhstan. *Int J Tuberc Lung Dis*. 2015;19:179–184. doi:10.5588/ijtld.14.0305
26. Marttila HJ, Marjamäki M, Vyshnevskaya E, et al. *pncA* mutations in pyrazinamide-resistant *Mycobacterium tuberculosis* isolates from northwestern Russia. *Antimicrob Agents Chemother*. 1999;43:1764–1766.
27. Jurén P, Werngren J, Toro JC, Hoffner S. Pyrazinamide resistance and *pncA* gene mutations in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2008;52:1852–1854. doi:10.1128/AAC.00110-08
28. Yüksel P, Tansel O. Characterization of *pncA* mutations of pyrazinamide-resistant *Mycobacterium tuberculosis* in Turkey. *New Microbiol*. 2009;32:153–158.
29. Daum LT, Konstantynovska OS, Solodiankin OS, et al. Characterization of novel *Mycobacterium tuberculosis* *pncA* gene mutations in clinical isolates from the Ukraine. *Diagn Microbiol Infect Dis*. 2019;93:334–338. doi:10.1016/j.diagmicrobio.2018.10.018
30. Muthaiah M, Jagadeesan S, Ayalusamy N, et al. Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of *Mycobacterium tuberculosis* from South India. *Int J Mol Sci*. 2010;11:2670–2680. doi:10.3390/ijms11072670
31. Chaidir L, Ruesen C, Dutilh BE, et al. Use of whole-genome sequencing to predict *Mycobacterium tuberculosis* drug resistance in Indonesia. *J Glob Antimicrob Resist*. 2019;16:170–177. doi:10.1016/j.jgar.2018.08.018
32. Aung WW, Ei PW, Nyunt WW, et al. Pyrazinamide resistance among multidrug-resistant *Mycobacterium tuberculosis* clinical isolates in Myanmar. *Antimicrob Agents Chemother*. 2018;62:e01984–17. doi:10.1128/AAC.01984-17
33. Jonmalung J, Prammananan T, Leechawengwongs M, Chairasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant *Mycobacterium tuberculosis* isolates from Siriraj Hospital, Thailand. *BMC Microbiol*. 2010;10:223. doi:10.1186/1471-2180-10-223
34. Gu Y, Yu X, Jiang G, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with *pncA*, *rpsA*, and *panD* gene mutations. *Diagn Microbiol Infect Dis*. 2016;84:207–211. doi:10.1016/j.diagmicrobio.2015.10.017
35. Li D, Hu Y, Werngren J, et al. Multicenter study of the emergence and genetic characteristics of pyrazinamide-resistant tuberculosis in China. *Antimicrob Agents Chemother*. 2016;60:5159–5166. doi:10.1128/AAC.02687-15
36. Cui Z, Wang J, Lu J, Huang X, Zheng R, Hu Z. Evaluation of methods for testing the susceptibility of clinical *Mycobacterium tuberculosis* isolates to pyrazinamide. *J Clin Microbiol*. 2013;51:1374–1380. doi:10.1128/JCM.03197-12
37. Ando H, Mitarai S, Kondo Y, et al. Pyrazinamide resistance in multidrug-resistant *Mycobacterium tuberculosis* isolates in Japan. *Clin Microbiol Infect*. 2010;16:1164–1168. doi:10.1111/j.1469-0691.2009.03078.x
38. Jnawali HN, Hwang SC, Park YK, et al. Characterization of mutations in multi- and extensive drug resistance among strains of *Mycobacterium tuberculosis* clinical isolates in Republic of Korea. *Diagn Microbiol Infect Dis*. 2013;76:187–196. doi:10.1016/j.diagmicrobio.2013.02.035
39. Huy NQ, Lucie C, Hoa TTT, et al. Molecular analysis of pyrazinamide resistance in *Mycobacterium tuberculosis* in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. *Emerg Microbes Infect*. 2017;6:e86. doi:10.1038/emi.2017.73
40. CRYPTIC Consortium and the 100,000 Genomes Project, et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. *N Engl J Med*. 2018;379:1403–1415. doi:10.1056/NEJMoa1800474

Infection and Drug Resistance**Dovepress****Publish your work in this journal**

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>